Novo Nordisk Hits $500bn; Tech Earnings Underwhelm; Tesla Slips

Every day, we handpick the 5 Top Stories stock market investors need to know. In 5 minutes, you’ll learn the stocks, CEOs, and money managers moving markets.

Novo Nordisk Passes $500bn (And Keeps Going)

After its share price extended gains following positive prognostications for Wegovy, its blockbuster anti-obesity drug, Novo Nordisk [NVO] on Wednesday became the second European company to surpass a market value of $500bn — only Dior-owner LVMH [MC:PA] has reached such heights….

Continue reading this news update.

Comments are closed